As a CenExel Center of Excellence, JBR works with patients who are managing challenging conditions, such as bunions. As a medical researcher in pain management, I have worked with many individuals that have participated in a bunion surgery at our surgical center in SLC, UT, and over the years I have developed a list of preventative treatments that I recommend to patients after surgery to help them keep their feet and toes happy and healthy. Here are my top tips for healthy feet . . .
News at CenExel
Analgesic efficacy and safety of naproxen sodium versus hydrocodone / acetaminophen in acute postsurgical dental pain
Analgesic efficacy and safety of naproxen sodium versus hydrocodone / acetaminophen in acute postsurgical dental pain: a randomized, double-blind, placebo-controlled trial Stephen A. Cooper (1), Paul J. Desjardins (2), Todd Bertoch (3), Engy Mikhail (4), Sistine...
RSV: Perspectives and Insight from a Healthcare Hero
As a former healthcare worker at Primary Children’s Hospital in Salt Lake City, UT, I begin to get more and more concerned about cold and flu season as it pertains to babies, as passing on a simple adult cold to an infant could be dangerous, even life-threatening....
Cali Biosciences Initiates Phase 2b Study of Long-Acting Ropivacaine for Non-Opioid Treatment of Post-Operative Pain
SAN DIEGO, August 12, 2021 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "CaliBio"), a global biopharmaceutical company focused on the research and development of innovative drugs, announced it has initiated a Phase 2b study of its...
Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™
Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™ SAN DIEGO, July 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company...
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours - ZYNRELEF is the first and only FDA-approved extended-release dual-acting local anesthetic, clinically proven to manage pain and to...